Merck & Co., Inc. (NYSE:MRK) Given New $142.00 Price Target at BMO Capital Markets

Key Points

• BMO Capital Markets raised its price target on Merck from $135 to $142 and kept an outperform rating, implying about 14.8% upside from the current share price.
• Other analysts have also turned more constructive, including Guggenheim lifting its target to $145 and Scotiabank to $155, while the stock’s overall consensus rating remains Moderate Buy.
• Merck’s latest quarter topped expectations, with EPS of -$1.28 versus an expected -$1.47 and revenue of $16.29 billion versus $15.85 billion estimated; the company also guided FY2026 EPS to 5.04-5.16.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price objective increased by investment analysts at BMO Capital Markets from $135.00 to $142.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. BMO Capital Markets' target price suggests a potential upside of 14.78% from the stock's current price.

Several other equities research analysts have also recently issued reports on MRK. Guggenheim raised their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a report on Monday. Morgan Stanley upped their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an "equal weight" rating in a research note on Thursday. Zacks Research upgraded Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Finally, Scotiabank upped their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a "sector outperform" rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $133.67.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $123.72 on Monday. The stock has a market capitalization of $305.56 billion, a P/E ratio of 34.85, a P/E/G ratio of 2.65 and a beta of 0.19. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $130.29. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The firm's 50-day moving average is $118.83 and its two-hundred day moving average is $116.36.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MRK. D.A. Davidson & CO. boosted its holdings in shares of Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company's stock valued at $60,731,000 after buying an additional 24,576 shares during the period. Farther Finance Advisors LLC raised its stake in Merck & Co., Inc. by 48.9% during the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company's stock worth $10,296,000 after acquiring an additional 32,114 shares during the period. Coldstream Capital Management Inc. lifted its holdings in Merck & Co., Inc. by 12.7% in the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company's stock worth $10,364,000 after acquiring an additional 13,940 shares during the last quarter. Campbell Capital Management Inc. bought a new position in Merck & Co., Inc. in the third quarter worth about $1,866,000. Finally, Norris Perne & French LLP MI boosted its stake in Merck & Co., Inc. by 12.8% in the fourth quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company's stock valued at $26,543,000 after acquiring an additional 28,635 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.